C Diff Drug Development
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints | Pfizer
Pre-specified secondary endpoint showed 0-11 vaccine to placebo case split for medically attended C. difficile infection (CDI), corresponding to 100% vaccine efficacy Median CDI duration was 1 versus 4 days and mean duration was 3 versus 16 days comparing vaccine to placebo, corresponding to a 75% and 80% reduction in disease episode, respectively, in vaccinated people Vaccine was very well tolerated and showed a favorable safety profile Trial did not meet its pre-specified primary endpoint of prevention of primary CDI, however, for all CDI cases recorded at 14 days post dose 3, vaccine efficacy was 49%, 47% and 31% up to 12 months, 24 months and at final analysis, respectively Company evaluating next steps for C. difficile vaccine program in coordination with regulatory agencies Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial ( CLO stridium difficile V accine E fficacy T R ial), a pivotal Phase 3 study evaluating its Clostridioides difficile ( C. difficile )
Microbiome therapeutic beats placebo for recurrent C. difficile - Medical Xpress
(HealthDay)—An investigational microbiome therapeutic composed of purified Firmicutes spores, SER-109, is superior to placebo for treatment of recurrent Clostridioides difficile infection, according ...
Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit
SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop
Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
Nature Medicine - Multi-modal profiling reveals major alterations in colonic B cells in patients with ulcerative colitis, including reduced clonal diversity of plasma cells, and suggests that...
Microbiome-Based Enema Effective for Recurrent C. difficile
A stool-based enema composed of a broad variety of microbes (RBX2660, Rebiotix/Ferring) was up to 84% effective in reducing recurrent emClostridioides difficile/em infection in a study of more than 720 adults with rCDI. br /p /p
Acurx Pharmaceuticals' Phase 2b Antibiotic Candidate To Treat C. Difficile Shows 100% Cure And 100% Sustained Cure In Potentially Transformative Study (NASDAQ: ACXP) - Digital Journal
Following a period of bearish conditions, investors are anxiously awaiting the next big rally. A return to normal levels would help revitalize investor portfolios and confidence following a difficult month for the markets. However, the return to bullish conditions may come sooner than many may believe –especially for those companies that navigated the situation wisely. […]
Therapeutic potential of miRNAs in Clostridioides difficile infection
Tweetable abstract Treating Clostridioides difficile infection with miRNAs alone or combined with live biotherapeutic products may augment therapeutic efficacy and help counteract drug resistance in the future.
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens
TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a …
An investigational oral microbiome treatment was 70% more effective than placebo in preventing CDI recurrence within 8 weeks of treatment. https://t.co/9o8lQcFGkw @DrPaulGastro #cdiff
An investigational oral microbiome treatment was 70% more effective than placebo in preventing CDI recurrence within 8 weeks of treatment. https://t.co/9o8lQcFGkw @DrPaulGastro #cdiff— Gastro & Endo News (@gastroendonews) February 17, 2022
Experimental spore therapy slashes C. difficile reinfection risk - Australian Doctor
An experimental three-day therapy that involves introducing Firmicutes spores into the gut may reduce the risk of Clostridium difficile reinfection by nearly 70%, a phase III trial shows. The treatment, known as SER-109, appeared to be more effective in patients under 65, which the US researchers say is “clinically important” given their increased risk of recurrent disease and hospital readmission. Most patients had a sustained clinical response 'out to about six months', researchers say.
Development of a double-antibody sandwich ELISA targeting the receptor binding domain of TcdB toxin of ST11 type Clostridium difficile of porcine origin
Clostridium difficile is an important zoonotic intestinal pathogen, which is widely present in humans and a variety of animals. The ST11 type C. difficile is one of the most widespread and harmful subtypes in the world. As a large country in pig farming, China lacks efficient methods f …
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial
In this phase 2a study, ten of ten patients achieved SCC, demonstrated favorable pharmacokinetics, minimal adverse events, and beneficial microbiome and bile acids results. These results support continued clinical development.
A Novel Bacteriophage with Broad Host Range against Clostridioides difficile Ribotype 078 Supports SlpA as the Likely Phage Receptor
Bacteriophages represent a promising option for the treatment of Clostridioides difficile (formerly Clostridium difficile) infection (CDI), which at present relies on conventional antibiotic therapy. The specificity of bacteriophages should prevent dysbiosis of the colonic microbiota associated with …
Bacteria as Therapeutics
4D Pharma has programs for treating irritable bowel syndrome (IBS) but also for cancer. 4D researchers have found, for example, that short chain fatty acids from M. massiliensis enhance the production of effector cytokines in CD8+ cells. Even more interestingly, 4D’s MRx0518 live biotherapeutic, is currently under investigation as an adjuvant treatment (with Keytruda) for a variety of cancers.
Use of a Clostridioides difficile Murine Immunization and Challenge Model to Evaluate Single and Combination Vaccine Adjuvants Consisting of Alum and NKT Cell-Activating Ligands
Adjuvant combinations may enhance or broaden the expression of immune responses to vaccine antigens. Information on whether established Alum type adjuvants can be combined with experimental CD1d ligand adjuvants is currently lacking. In this study, we used a murine Clostridioides difficile im …
New England Journal of Medicine Publishes Data from ECOSPOR III Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection | Seres Therapeutics
The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.
Dissection and enhancement of prebiotic properties of yeast cell wall oligosaccharides through metabolic engineering
Saccharomyces boulardii is a yeast clinically used for treating various symptoms of gastrointestinal dysbiosis. Despite their genomic relatedness, S. boulardii has a distinctive cell wall oligosaccharide composition compared to baker's yeast S. cerevisiae, such as higher mannan content. Here we expl …
MyBiotics announces successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, driving an innovative path to new restoration therapies using microbiome culturing technology - PRNewswire
/PRNewswire/ -- MyBiotics Pharma Ltd, a clinical stage microbiome therapeutics company, today announced the successful completion of Phase I clinical trial of...
